ConductScience.org, home

Paper8375017

Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Denny WA and 1 other. Cancer Metastasis Rev, 1993. Cited by 70 papers, by iCite.

Cite this record

ConductScience Library. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Papers, record 8375017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8375017

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
PubMed
Journal
Cancer Metastasis Rev
PubMed
Year
1993
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
70
iCite
Relative citation ratio, by iCite
2.13
iCite
Revised in PubMed
2019-11-01
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Denny WAW A
2Wilson WRW R

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CytotoxinsMajor topic
NeoplasmsMajor topic
Nitrogen Mustard CompoundsMajor topic
ProdrugsMajor topic
Animals
Cell Cycle
Cell Hypoxia
Diffusion
Drug Design
Humans
Molecular Structure
Oxidation-Reduction

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CM 07321NCI NIH HHSUnited StatesPubMed

Source PubMed

Download CSV of grants

References67

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13280413Reoxygenation and repopulation in irradiated tumors.Front Radiat Ther Oncol1988https://conductscience.org/library/papers/3280413PubMed
27236492A marker for hypoxic cells in tumours with potential clinical applicability.Br J Cancer1981https://conductscience.org/library/papers/7236492PubMed
31586589Use of a high frequency ultrasound microscope to image the action of 2-nitroimidazoles in multicellular spheroids.Br J Cancer1992https://conductscience.org/library/papers/1586589PubMed
42244016The effects of single dose oral hydralazine on blood flow through human lung tumours.Radiother Oncol1990https://conductscience.org/library/papers/2244016PubMed
5356975Cell kinetics and chemotherapy: a critical review.Cancer Treat Rep1978https://conductscience.org/library/papers/356975PubMed
62587812Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069.Radiother Oncol1989https://conductscience.org/library/papers/2587812PubMed
71913664Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.Cancer Res1991https://conductscience.org/library/papers/1913664PubMed
8679180Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells.Cancer Res1978https://conductscience.org/library/papers/679180PubMed
91617656Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution.Cancer Res1992https://conductscience.org/library/papers/1617656PubMed
101562278The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink.Biochem Pharmacol1992https://conductscience.org/library/papers/1562278PubMed
112083666Antibody-directed enzyme/prodrug therapy (ADEPT).Biochem Soc Trans1990https://conductscience.org/library/papers/2083666PubMed
123360652Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy.Int J Radiat Oncol Biol Phys1988https://conductscience.org/library/papers/3360652PubMed
131671692Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid.Int J Radiat Biol1991https://conductscience.org/library/papers/1671692PubMed
142545340Acid pH in tumors and its potential for therapeutic exploitation.Cancer Res1989https://conductscience.org/library/papers/2545340PubMed
151727119Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.Int J Radiat Oncol Biol Phys1992https://conductscience.org/library/papers/1727119PubMed
161930294Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species.Biochem Pharmacol1991https://conductscience.org/library/papers/1930294PubMed
173175048Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.Radiother Oncol1988https://conductscience.org/library/papers/3175048PubMed
18482607Radiation survival of cells from spheroids grown in different oxygen concentrations.Radiat Res1979https://conductscience.org/library/papers/482607PubMed
197313077Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide).Radiat Res1981https://conductscience.org/library/papers/7313077PubMed
203202902
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Biochem Pharmacol1988https://conductscience.org/library/papers/3202902PubMed

See all 67 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.

PMIDTitleJournalYearIn PapersSource
34835785The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors.Nanomaterials (Basel)2021https://conductscience.org/library/papers/34835785PubMed
33915222Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.J Control Release2021https://conductscience.org/library/papers/33915222PubMed
33897898Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy.Theranostics2021https://conductscience.org/library/papers/33897898PubMed
31190820Hypoxia-active nanoparticles used in tumor theranostic.Int J Nanomedicine2019https://conductscience.org/library/papers/31190820PubMed
30672949Physical properties, ligand substitution reactions, and biological activity of Co(iii)-Schiff base complexes.Dalton Trans2019https://conductscience.org/library/papers/30672949PubMed
30575832Hypoxia-targeted drug delivery.Chem Soc Rev2019https://conductscience.org/library/papers/30575832PubMed
30111719Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs.Molecules2018https://conductscience.org/library/papers/30111719PubMed
24409417Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Front Oncol2013https://conductscience.org/library/papers/24409417PubMed
24109591The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Front Oncol2013https://conductscience.org/library/papers/24109591PubMed
22289471Redox activation of metal-based prodrugs as a strategy for drug delivery.Adv Drug Deliv Rev2012https://conductscience.org/library/papers/22289471PubMed
19924084Bystander or no bystander for gene directed enzyme prodrug therapy.Molecules2009https://conductscience.org/library/papers/19924084PubMed
12386828
Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
Cancer Gene Ther2002https://conductscience.org/library/papers/12386828PubMed
10815768Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.J Comput Aided Mol Des2000https://conductscience.org/library/papers/10815768PubMed
8763845Pulse radiolysis studies on the hypoxia-selective toxicity of a colbalt-mustard complex.Br J Cancer Suppl1996https://conductscience.org/library/papers/8763845PubMed
8763842Recent developments in the design of bioreductive drugs.Br J Cancer Suppl1996https://conductscience.org/library/papers/8763842PubMed
8611431Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.Br J Cancer1996https://conductscience.org/library/papers/8611431PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8375017

GET https://conductscience.org/api/papers/v1/8375017/references?page=2